Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
yes ... but its the license of the chips the target is the software written by the user so its infinite
Scancell develop the platform and license the targets same principle it does not sell or manufacture
both would have royalty streams
but always retain the core .. the platforms or the chip design
well we can rule out dilution as a discussion !!!
more time spent on orange juice than Spain took to grow them ...
can rule out "Risky" .... what does that mean ... keep an eye on Risky ... ? you buy or you don't there is No Risky half in half out share ...
Arm Holdings ... mine
.... Kate Cornish Bowden ... wonder what she is up to ... legs discussion ?
lol
another rec from Nana's Kitchen
https://www.pataks.co.uk/products/oven-bakes/tikka
authentic ... !! cook up some onions with Garlic first then Bake diced chicken after marinade
talking of Curries ... i tried this place https://www.thai-food-online.co.uk/collections/thai-green-curry-pastes
I tub made 4 frozen meals ......... so spicey i had to dilute each meal by two with a tin of tomatoes and it still makes me sweat and it gets stronger after defrost ........ wow ! what a Taste
Its really important that investors when looking at Scancell consider secondary effect .. by flipping the environment of cancer to pro inflammatory you are also bringing into play other active members of the immune system
so Avidmab could trigger an adaptive immune response ............... ie The MAB never meets the t cell but activates it via the Molecular damage it causes ...
Avidmab also can utilise "DAMPS" ... to spark an immune response by releasing DAMPS into the environment
PAMPS and DAMPs both activate similar Pathways of the Innate Immune system
""""Once these PAMPs bind to their receptors, a signaling cascade is triggered that, among others, leads to the activation of cells that initiate a potent acquired immune response."""
no no amplivant is vital in how the DC encodes the T cells .. however the migration of the peptide i assume via the innate system maybe be also influenced by the adjuvant .. TRL2 conjugated to the peptide
TLRs expressed by immune cells such as dendritic cells (DCs) or macrophages play a key role in innate immunity. They recognize characteristic molecular structures present on the surface of bacteria, called pathogen associated molecular
patterns (PAMPs). Once these PAMPs bind to their receptors, a signaling cascade is triggered that, among others, leads to the activation of cells that initiate a potent acquired immune response.
https://www.isa-pharma.com/technology/amplivant-technology/
https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0455-2
Co-stimulation is a secondary signal which immune cells rely on to activate an immune response in the presence of an antigen-presenting cell.[1] In the case of T cells, two stimuli are required to fully activate their immune response. During the activation of lymphocytes, co-stimulation is often crucial to the development of an effective immune response. Co-stimulation is required in addition to the antigen-specific signal from their antigen receptors.
https://en.wikipedia.org/wiki/Co-stimulation#:~:text=3%20Applications-,T%20Cell%20Co%2Dstimulation,antigen%20presenting%20cells%20(APC).